Figure 7. Immunofluorescence staining of the lumbar spinal cord section of SOD1G93A transgenic mouse transplanted with F3.Olig2-Shh cells.
Image credit: Lee, et.al. 2014 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Somatic Cell Genome Editing Program
Sponsor: NIH
Description: The NIH Common Fund’s Somatic Cell Genome Editing program aims to develop quality tools to perform effective and safe genome editing in human patients. These research tools will be made widely available to the research community to reduce the time and cost required to develop new therapies. Multiple funding opportunities are available to fund projects including: better animal models for assessing genome editing in vivo, tools and assays to detect adverse consequences of genome editing in human cells, new technologies to deliver genome editing machinery into disease relevant cells and tissues in vivo and novel genome editing and engineering systems.
Deadline: Letter of Intent due by March 3, 2018.



NEW! Early Career Awards
Sponsor: Brain Canada and the Azrieli Foundation
Description: Brain Canada Foundation and the Azrieli Foundation are excited to announce a new open call for funding, the Early-Career Capacity Building Grants. The general goal of the Early-Career Capacity Building Grant program is to accelerate novel and transformative research that will fundamentally change our understanding of nervous system function and dysfunction and their impact on health. This program will provide $100,000 over 2 years to Early-Career Researchers, within 3 years of their first research or university appointment, that will enable innovative and original research with the high potential for a meaningful impact.
Deadline: Application due by April 17, 2018.



NEW! Rapid Response: Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Rapid Response: Canada is seed funding for high risk, high reward projects focusing on neurodegenerative diseases including FTD. Preliminary or supporting data is not required. Projects can be from $10,000 to 200,000. Applicants must be working in Canada at least 30% of the time at or above the level of postdoctoral researcher, and be affiliated with a Canada Revenue Agency-qualified institution.
Deadline: Letter of Intent due by April 19, 2018.



NEW! Rapid Response: Ireland, Netherlands, UK (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Rapid Response: Ireland, Netherlands, UK 2018 (Fluid Biomarkers) program was launched to provide seed funding, without requirement for preliminary data, to support high-risk, high-reward, translational research on novel biomarkers detected in patient-derived fluids. Up to £180,000 over up to 18 months per project will be awarded, with a total of £540,000 available for the full program. Principal Applicants must be at or above the level of Postdoctoral Researcher and at eligible institutions located in Ireland, the Netherlands, or the UK.
Deadline: Letter of Intent due by April 23, 2018.



NEW! Graduate Studentships
Sponsor: MND Association
Description: The MND Association supports biomedical research on Amyotrophic Lateral Sclerosis and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. This grant supports the training of a graduate science student in order to achieve the qualification of PhD (or equivalent) in a subject of direct relevance to motor neurone disease. Applications will begin to be accepted March 9, 2018.
Deadline: Application due by May 4, 2018.



NEW! Non-Clinical Fellowships
Sponsor: MND Association
Description: We now invite post-doctoral scientists with relevant experience who are ready to lead a research project as Principal Investigator, to apply for an MND Association Non-clinical Fellowship Award. These awards will be open to scientists across a range of disciplines, excluding those with a medical qualification. The award may only be held at a university or other bona-fide research institute in the UK and Ireland – the host institute. Applications will begin to be accepted March 9, 2018.
Deadline: Application due by May 4, 2018.



NEW! ALS Canada Project Grant Program
Sponsor: ALS Canada
Description: This grant program funds the best projects including high risk/high reward with little preliminary data, continuation of ongoing high quality research and studies to improve the quality of life for people with ALS. Grants anticipated to be $125,000 CAD for use over 1 or 2 years.
Deadline: Application due by June 8, 2018.



MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by March 1, 2018.



Health and Social Care for Neurodegenerative Diseases
Sponsor: EU Joint Programme – Neurodegenerative Disease Research (JPND)
Description: JPND is inviting multi-national research teams to submit proposals for ambitious, innovative and multi-disciplinary collaborative projects in the European Union (EU) that address health and social care at both the macro level of systems and infrastructures and the individual level of patients, carers and families.
Deadline: Pre-Proposals due by March 6, 2018.



Rapid Response: Canada 2018
Sponsor: Weston Brain Institute
Description: This program provides seed funding for high-risk, high-reward, translational research projects on neurodegenerative diseases of aging including FTD.   A maximum of $200,000 over up to 18 months per project. Principal applicants must be researchers working in Canada at least 30% of the time above the level of Postdoctoral Fellow, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Applications are expected to begin to be accepted in February 2018.
Deadline: Letter of Intent due by April 2018.



Rapid Response: Ireland, Netherlands, UK 2018
Sponsor: Weston Brain Institute
Description: Provides seed funding up to £175,000 per project for over up to 2 years for novel, high-risk, high-reward translational research projects that accelerate the development of therapeutics for neurodegenerative diseases of aging including FTD based in Europe. Applications will begin to be accepted in January 2018.
Deadline: Application due by April 2018.



Research Grants
Sponsor: Fight MND
Description: These grants support the preclinical research, development, and assessment of therapeutics for MND through to (and including) completion of Phase I clinical trials. These grants are each awarded with an offer of up to AUD $1,000,000 in support available for 3-year projects. Researchers globally are invited to apply.
Deadline: Application due by April 1, 2018.



Graduate Student Fellowship
Sponsor: AFM-Téléthon
Description: This International Call for Proposals, open to both French and foreign groups, aims to support research at the graduate student level which will increase our understanding of the neuromuscular system or encourgae the development of therapies for neuromuscular diseases and rare genetic diseases. Special attention will be given to: (1) projects on epigenetics in neuromuscular diseases and (2) projects on microbiota in neuromuscular diseases. Priority will be given to ALS research projects that could be also provide insight into the underlying mechanisms and/or treatment of SMA.
Deadline: Application due by April 24, 2018.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



Identify, Analyze and Evaluate Potential Risk Factors for ALS
Sponsor: CDC
Description: The purpose of this funding opportunity announcement (FOA) is to allow for investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the National ALS Registry's mission. Maximum award is $400,000 USD. Note: This is a forecasted opportunity.
Deadline: February 16, 2018 (estimated).



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Transformational Research: Canada 2018
Sponsor: Weston Brain Institute
Description: This program funds transformative, novel, high-risk, high-reward translational research projects with excellent preliminary data aimed at accelerating the development of therapies for neurodegenerative diseases of aging including FTD. A maximum of $1,500,000 over up to 3 years per project. PIs must be at or above the level of Assistant Professor or equivalent, work in Canada at least 30% of the time, and be affiliated with a CRA-qualified institution.
Deadline: February 15, 2018 (extended).



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail